<DOC>
	<DOCNO>NCT00533442</DOCNO>
	<brief_summary>This study design determine immunosuppressive agent , rapamycin mycophenalate mofetil , result well outcome patient type 1 diabetes renal failure , present kidney-pancreas transplant .</brief_summary>
	<brief_title>Rapamycin Versus Mycophenolate Mofetil Kidney-Pancreas Recipients</brief_title>
	<detailed_description>This randomize , prospective single center study evaluate two drug .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Patient Type 1 diabetes end stage renal disease . Women childbearing potential must negative pregnancy test ( serum urine ) . Patient agree participate study sign inform consent . Patient known contraindication administration rapamycin mycophenolate mofetil . Patient history hypersensitivity rapamycin mycophenolate mofetil . Patient history malignancy within two year , exception adequately treat localized squamous basal cell carcinoma skin without evidence recurrence . Patient currently abuse drug alcohol . Patient know suspect active infection seropositive hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Rapamycin</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>kidney-pancreas transplant</keyword>
</DOC>